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Mailing address: Frances E. Lund, PhD receptor CD21. Underscoring these phenotypic differences, we interrogated the morphology of 1 1 7 H1 pos T-bet hi Bmem using ImageStream and found them to be larger and more granular than 1 1 8 H1 pos T-bet lo Bmem (Supplemental Fig 1E) .
9
Ki67 is not a binary marker of proliferation and its expression at any individual timepoint 1 2 0
does not necessarily reflect ongoing or future proliferative potential but may rather reflective in the circulation within one month of IIV (Figure 1C, 1E) . However, we did not consistently 1 2 7
observe a parallel expansion in the HA pos T-bet lo Bmem fraction in this cohort ( Figure 1D , 1F).
2 8
We found an exclusive correlation between the day 7 cTfh and the day 7 HA pos T-bet T-bet is a lineage defining master transcriptional regulator of terminally differentiated 1 3 6
effector cell subsets 32, 33 and its role in B cell differentiation has been studied in various 1 3 7
pathologic in vivo and in vitro contexts. 8, 19, 20, [23] [24] [25] [26] [27] [28] [29] Murine studies of influenza infection in wild-1 3 8
type versus B-Tbx21 -/-chimeric mice demonstrate that T-bet is necessary for long-lived IgG2c 1 3 9
antibody production after primary infection and dispensable for the development and distinguishes effector from central memory, CCR7. 47 We compared our transcriptional analysis 1 7 3
to curated gene lists of cell cycle genes and apoptosis genes (Qiagen RT2 profiler) ( Figure 2C ).
7 4
Expectedly we found that the vaccine elicited PBs, which are known to proliferate and are short-1 7 5
lived, had differential expression at a number of cell cycle and apoptosis genes. Consistent with 1 7 6
transient expression of Ki-67 over time in the HA pos T-bet hi Bmem, we did not find significant 1 7 7
differences in cell cycle genes between day 7 H1 pos T-bet hi and day 7 H1 pos T-bet lo Bmem.
7 8
Consistent with terminal effector cell remodeling, we found that day 7 H1 pos T-bet hi Bmem 7 days of vaccine receipt in each year. We found a significant increase in HA-titer after vaccine 3 5 9
( Figure 5E ), demonstrating that all 10 subjects responded to the prime and had relatively high 3 6 0 titers of HA-Ab prior to vaccine boost. We found that re-vaccination contracted the HA pos T-bet 
9 2
In the context of vaccination against influenza, atypical memory B cells have been 3 9 3
identified in the HA-specific Bmem compartment with T-bet expression. 19, 20 Our study is 3 9 4
distinguished from these previous reports because we did not discern a pre-ASC transcriptional 3 9 5 signature in the atypical Bmem compartment after IIV. Rather we found that the antigen-specific 3 9 6
T-bet hi Bmem subset to retain transcriptional and epigenetic programming as effector memory.
9 7
This discrepancy in findings may pertain to differences in study design with respect to the existing Ab mediate epitope masking or epitope clearance. 102 We did not observe a reduction in 4 5 8
the total or T-bet lo HA pos Bmem fraction after re-vaccination ( Figure 5F ). This discrepancy from 4 5 9
prior reports may be due to our directly enumerating the antigen-specific Bmem compartment 
6 4
It is interesting to note that large lineages from the circulating 2016 D7 HA pos T-bet hi 4 6 5 subset were not consistently recalled into the 2017 PB compartment after repeat IIV [ Figure 5K ].
6 6
The fate of these large clonotypes is not clear. [ Figure 5L ]. Elucidating clonotypic relationships among effector and central HA-specific Bmem 4 7 5
at various human tissue sites (blood, lymphoid, mucosal) and with the circulating flu-specific Ig 4 7 6
repertoire will be an important goal of future studies.
7 7
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9 6
Materials and Methods: 4 9 7
Human Subjects and Samples. The UAB Institutional Review Board approved all study 4 9 8 protocols for influenza vaccinated subjects. All subjects gave written informed consent as part of 
0 5
Lymphocyte and plasma isolation. Peripheral blood from human subjects was drawn into K2- detect HA-binding B cells, cells were treated at 37C with 0.5U/ml neuraminidase (C.
7 8
Polymerase Master Mix (KAPA Biosystems). Amplified, low molecular weight DNA was isolated 5 7 9
using another SPRI-bead size selection. Quality control was performed on a bioanalyzer.
8 0
Libraries were sequenced using a 50bp paired end run at the UAB Heflin Genomics Center.
8 1
Raw sequencing reads were mapped to the hg38 version of the human genome using Bowtie Illumina MiSeq: HA-specific Bmem and plasmablasts were sort-purified into RLT buffer and 5 9 0 snap frozen in liquid nitrogen. RNA was extracted using the quick start protocol from QIAGEN 5 9 1
RNeasy Mini Kit. First strain cDNA synthesis was performed using iScript cDNA synthesis kit 5 9 2
(BioRad) and 8ul of RNA following manufacturer protocol. First round amplification of IgG, IgA, 5 9 3
and IgM was performed in a 25 ul reaction volume using 4-8 ul cDNA, Platinum PCR SuperMix
9 4
High Fidelity (Invitrogen), and 1ul gene specific primers (120 nM) of Vn1-Vh7 FR1 (forward) and 5 9 5
Ca, Cu, Cg (reverse). First round PCR conditions were: 95C for 3 min, 42 cycles of 30s 95C, 5 9 6 30s 58C, 30s 72C, and 72C for 3 minutes. Amplification was verified using 1.2% agarose gels 5 9 7
(Lonza). Samples were ligated in a second round PCR with Nextera Index kit (Illumina). PCR2 5 9 8
conditions for indexing were: 72C for 3 minutes, 98C for 30s and 5 cycles of 98C for 10s, 63C 5 9 9
for 30s, and 72 C for 3 minutes. Products were purified with Agencourt AMPure XP beads 6 0 0 (blue, n=5), and D7 H1 neg T-bet hi Bmem (pink, n=3) were sort-purified from healthy subjects after 6 8 8
2018 IIV for analysis of chromatin accessibility by ATAC-seq. Fcrl5 was used as a cell surface 6 8 9
surrogate for T-bet expression (see Supplemental Fig 2) . Principal component analysis of target genes of IRF4 in human plasma cells 51 was assessed in each population sorted for 6 9 3
ATAC-seq as shown in Figure 2E . T-bet lo Bmem network were identified using PageRank (PR) analysis. PR log fold change (FC) 6 9 6
versus differential gene expression (DEG) by RNA-seq analysis of these TFs is depicted. 6 9 7 6 9 8
Statistical analysis was performed using two-way ANOVA (B) and multiple t-test testing (F). *p< 6 9 9 0.05, **, p<0.01, *** p<0.001, **** p <0.0001 ns= non-significant Bmem network over D7 PB network were identified and shown as PR log fold change plotted 7 1 9
against DEGs from RNA-seq data set (see Figure 2) . 
2 3
Representative GSEA plots from each of these clusters, labeled 1-3, is shown.
2 4
(G) Ingenuity pathway analysis (IPA) was performed on the genes that comprised clusters 2.
2 5
Predicted upstream regulators of cluster 2 are shown in a bar plot with bar color indicating z-7 2 6
score. Regulators that are predicted with bias are demarcated with a dot above that regulator.
2 7
(H) Genome plot of chromatin accessibility for the XBP1 locus is shown in D7 PB, D7 H1 pos T- Statistical analysis was performed using one-way ANOVA testing (B, C). *p< 0.05, **, p<0.01, 7 3 3 *** p<0.001, **** p <0.0001 ns= non-significant 7 3 4 7 3 5 7 3 6 (F-S) These data refer to correlations between various subsets among 19 healthy subjects who 8 2 7
received the 2015 IIV that included the California H1 (Ca-H1) and Switzerland (Sw-H3) 8 2 8
antigens.
2 9
(F-I) Correlations between the fold change in cTfh from day 0 to day 7 after IIV with percent day 8 3 0
7 antigen specific (Ca-H1 or Sw-H3) T-bet hi and T-bet lo Bmem out of the total NPC gate. percent day 7 Ca-H1 pos T-bet hi Bmem subset from the parent NPC gate.
3 6
(M) Correlation between the fold change in H1 IgG titer from day 0 to day 120 after IIV and the 8 3 7
percent day 7 Sw-H3 T-bet hi Bmem subset from the parent NPC gate.
3 8
(N) Correlation between the fold change in H1 titer from day 0 to day 120 after IIV and the 8 3 9
percent day 14 Ca-H1 pos T-bet hi Bmem subset from the parent NPC gate. 14 Sw-H3 T-bet hi Bmem subset from the parent NPC gate.
4 6
(R) Correlation between the fold change in H1 IgG from day 0 to day 120 and the percent day 8 4 7
14 Sw-H3 T-bet hi Bmem subset from the parent NPC gate.
4 8
(S) Correlation between the fold change in H3 IgG from day 0 to day 120 and the day 14 Sw-H3 8 4 9
T-bet lo Bmem subset from the parent NPC gate. were sort-purified for ATAC-seq using Fcrl5 as a cell surface surrogate for T-bet expression .
7 3
Principal component analysis of these data is show here.
7 4
(E) Defined as Reads per Peak per Million (RPPM), accessibility at genes known to function as 8 7 5
target genes of IRF4 in human plasma cells 51 was assessed in each population sorted for 8 7 6
ATAC-seq as shown in Supplemental Figure 2D . A   CDK4  GADD45A  CCNC  STMN1  CKS1B  MCM2  CCND2  CASP3  MCM3  KPNA2  SERTAD1  CHEK2  CDK2  MDM2  KNTC1  RBBP8  ATM  CCNG2  WEE1  AURKA  RAD51  CDKN2A  CDKN2C  CCNE1  BRCA1  CDC25C  CDC25A  CHEK1  GTSE1  BRCA2  TFDP2  CDK6  AURKB  CCNA2  BIRC5  CDC6  CCNB2  CDK1  MKI67  CDC20  CCNB1  CCNF  MAD2L1  MCM4  CDKN3  BCL2  CDK5R1  CCND1  RB1  MCM5  E2F4  RBL2  CKS2  ABL1  MRE11A  RBL1  CDKN1B  ATR  RAD1  CDK7  CCNT1  ANAPC2  CDK8  CUL3  CCNH  CUL2  TP53  HUS1  RAD9A  MNAT1  SKP2  CDC34  CDK5RAP1  NBN  BCCIP  MAD2L2  CCNG1  CDC16  RAD17  TFDP1  CCND3  CDKN1A  CUL1   Cell Cycle   CYLD  TRAF2  ATG5  BAG1  BIRC2  CTSB  TRADD  GADD45A  ATG12  CASP2  TP53  ATG16L1  BCL10  BAD  RIPK2  GAA  CASP1  DENND4A  AIFM1  CASP7  BCL2L11  CASP6  EIF5B  PARP2  BID  CASP10  FADD  ABL1  C1orf159  PIK3C3  TXNL4B  SPATA2  BRAF  ATG7  BFAR  CASP9  DIABLO  TMEM57  BNIP3  BCL2L1  CRADD  APAF1  HSPBAP1  BIRC6  DFFA  RPS6KB1  TP53BP2  TRAF3  CFLAR  COMMD4  TNFSF10  NFKB1  HRK  HTT  MAP1LC3A  NOD1  TNFRSF10B  FAS  AKT1  BAG3  APP  BCL2  BMF  TNFSF8  ULK1  XIAP  CD70  TNFRSF25  DAPK1  ESR1  TP73  IGF1  IGF1R  NAIP  MAPK8  TNFRSF1A  TNF  BIK  BIRC5  ATG3  CASP4  BAX  BNIP3L  CYCS  BECN1  SQSTM1  PYCARD  CASP8  BIRC3  TNFRSF10A  CD40  BCL2A1  BAK1  CASP3  BNIP2  MCL1  CTSS  GRB2  PARP1  TNFRSF1B CREB3  SEL1L  SIL1  MANF  VIMP  CALR  RPN1  PDIA3  CANX  VCP  HSPA5  XBP1  HERPUD1  PPIA  PPP1R15A  ATF6B  SREBF1  ATXN3  MBTPS2  RNF5  CEBPB  MAPK9  HSPA2  KCNMB3  MAPK8  DNAJC3  MCM4  ERN1  GINS2  TYMS  UHRF1  RRM2  PRKCSH  SYVN1  ERP44  MBTPS1  CCT4  HSPA4  UBE2G2  NUCB1  UBXN4  BAX  HSPH1  DDIT3  ATF4  DNAJC10  GANAB  OS9  DNAJB9  SERP1  EDEM1  PFDN5  EIF2AK3  HSPA1B  AMFR  ASNS  DERL1  USP14  TOR1A  INSIG2  SEC62  SCAP  NPLOC4  EIF2A  SEC63  PCNA  ATF6  UFD1L  HTRA2  UGGT1  FBXO6  TRIB3  BEX2  GANC Lineage Size (%)
